Failure of liposomally encapsulated Adriamycin to improve therapeutic efficacy for cancer cells in vitro

References

• Abra R. M., Hunt C. A., Fu K. K., Peters J. H. Delivery of therapeutic doses of Doxorubicin to the mouse lung using lung-accumulating liposomes proves unsuccessful. Cancer Chemotherapy and Pharmacology 1983; 11: 98–101
   PubMed Web of Science ®Google Scholar
• Busch H., Fujiwara E., Firszt D. C. Studies on the metabolism of radioactive albumin in tumour-bearing rats. Cancer Research 1961; 21: 371–377
   PubMed Web of Science ®Google Scholar
• Crommelin D. J. A., Slaats N., Van Bloois L. Preparation and characterization of Doxorubicin-containing liposomes I. Influence of liposome charge and pH of hydration medium on loading capacity and particle size. International Journal of Pharmaceutics 1983; 16: 79–92
   Web of Science ®Google Scholar
• Crooke S. T., Duverney V. H., Mong S. Molecular pharmacology of anthracyclines. Molecular Actions and Targets for Cancer Chemotherapeutic Agents, A. C. Sartorelli. Academic Press. 1981; 137–162
   Google Scholar
• Damen J., Regts J., Scherphof G. Transfer and exchange of phospholipid between small unilamellar vesicles and rat plasma HDL. Dependence on cholesterol content and phospholipid composition. Biochimica et Biophysica Acta 1981; 665: 538–545
   PubMed Web of Science ®Google Scholar
• Duarte-Karim A., Ruysschaert J. M., Hildebrand J. Affinity of Adriamycin to phospholipids: a possible explanation for cardiac mitochondrial lesions. Biochemical and Biophysical Research Communications 1976; 71: 658–663
   PubMed Web of Science ®Google Scholar
• Eichholtz-Wirth H. Dependence of the cystostatic effect of Adriamycin on drug concentration and exposure time in vitro. British Journal of Cancer 1980; 41: 886–891
   PubMed Web of Science ®Google Scholar
• Forssen E. A., Tokes Z. A. In vitro and in vivo studies with Adriamycin liposomes. Biochemical and Biophysical Research Communications 1979; 91: 1295–1301
   PubMed Web of Science ®Google Scholar
• Forssen E. A., Tökes Z. A. Use of anionic liposomes for the reduction of chronic Doxorubicin-induced cardiotoxicity. Proceedings of the National Academy of Sciences, U.S.A. 1981; 78: 1873–1877
   PubMed Web of Science ®Google Scholar
• Forssen E. A., Tökes Z. A. Improved therapeutic benefits of Doxorubicin by entrapment in anionic liposomes. Cancer Research 1983; 43: 546–550
   PubMed Web of Science ®Google Scholar
• Gabizon A., Dagan A., Goren D., Barenholz Y., Fuks Z. Liposomes as in vivo carriers of Adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Research 1982; 42: 4734–4739
   PubMed Web of Science ®Google Scholar
• Gabizon A., Goren D., Fuks Z., Barenholz Y., Dagan A. Enhancement of Adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers. Cancer Research 1983; 43: 4730–4735
   PubMed Web of Science ®Google Scholar
• Ganapathi R., Krishan A. Effect of cholesterol content of liposomes on the encapsulation, efflux and toxicity of Adriamycin. Biochemical Pharmacology 1984; 33: 698–700
   PubMed Web of Science ®Google Scholar
• Goohmaghtigh E., Chatelain P., Caspers J., Ruysschaert J. M. Evidence of a specific complex between Adriamycin and negatively charged phospholipids. Biochimica et Biophysica Acta 1980; 597: 1–14
   PubMedGoogle Scholar
• Gregoriadis G. The carrier potential of liposomes in biology and medicine. New England Journal of Medicine 1976; 295: 704–710
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. Targeting of drugs with molecules, cells and liposomes. Trends in Pharmacological Science 1983a; 4: 304–307
   Web of Science ®Google Scholar
• Gregoriadis G. Liposomes as drug carriers. Pharmacy International 1983b; 4: 33–37
   Google Scholar
• Juliano R. L., Stamp D. The effect of particle size and charge on the clearance rates of liposomes and liposome-encapsulated drugs. Biochemical Biophysical Research Communications 1975; 63: 651–658
   PubMed Web of Science ®Google Scholar
• Kirby C., Clarke J., Gregoriadis G. Effect of cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochemical Journal 1980a; 186: 591–598
   PubMed Web of Science ®Google Scholar
• Kirby C., Clarke J., Gregoriadis G. Cholesterol content of small unilamellar liposomes controls phospholipid loss to HDL in the presence of serum. FEBS Letters 1980b; 111: 324–328
   PubMed Web of Science ®Google Scholar
• Knoche H. Leitfaden der histologischen Technik. G. Fischer, Stuttgart 1979
   Google Scholar
• Lowry O. H., Rosebrough N. J., Farr A. C., Randall R. J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Machy P., Leserman L. D. Small liposomes are better than large liposomes for specific drug delivery in vitro. Biochimica et Biophysica Acta 1983; 730: 313–320
   PubMed Web of Science ®Google Scholar
• Malorny U., Neumann C., Sorg C. Influence of various detachment procedures on the functional state of cultured murine macrophages. Immunobiology 1981; 159: 327–336
   PubMed Web of Science ®Google Scholar
• Matthay K. K., Heath T. D., Papahadjopoulos D. Specific enhancement of drug delivery to AKR lymphoma by antibody-targeted small unilamellar vesicles. Cancer Research 1984; 44: 1880–1886
   PubMed Web of Science ®Google Scholar
• Olson F., Hunt C. A., Szoka F. C., Vail W. J., Papahadjopoulos D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochimica et Biophysica Acta 1979; 557: 9–23
   PubMed Web of Science ®Google Scholar
• Olson F., Mayhew E., Maslow D., Rustum Y., Szoka F. Characterization, toxicity and therapeutic efficacy of Adriamycin encapsulated in liposomes. European Journal of Cancer and Clinical Oncology 1982; 18: 167–176
   PubMedGoogle Scholar
• Pagano R. E., Weinstein J. N. Interactions of liposomes with mammalian cells. Annual Review of Biophysics and Bioengineering 1978; 7: 435–468
   PubMedGoogle Scholar
• Peterson C., Trouet A. Transport and storage of Daunorubicin and Doxorubicin in cultured fibroblasts. Cancer Research 1978; 38: 4645–4649
   PubMed Web of Science ®Google Scholar
• Poste G., Papahadjopoulos D. Drug-containing lipid vesicles render drug-resistant tumour cells sensitive to Actinomycin D. Nature 1976; 261: 699–701
   PubMed Web of Science ®Google Scholar
• Rahman A., Kessler A., More N., Sikic B., Rowden G., Woolley P., Schein P. S. Liposomal protection of Adriamycin-induced cardiotoxicity in mice. Cancer Research 1980; 40: 1532–1537
   PubMed Web of Science ®Google Scholar
• Rogers K. E., Tokes Z. A. Novel mode of cytotoxicity obtained by coupling inactive anthracycline to a polymer. Biochemical Pharmacology 1984; 33: 605–608
   PubMed Web of Science ®Google Scholar
• Rosa P., Clementi F. Absorption and tissue distribution of Doxorubicin entrapped in liposomes following i.v. or i.p. administration. Pharmacology 1983; 26: 221–229
   PubMed Web of Science ®Google Scholar
• Sauk J. J., Witkop C. J. Expression of melanoma neutral proteinase and collagenase potential by endocytosis. Biochemical Biophysical Research Communications 1978; 83: 144–150
   PubMed Web of Science ®Google Scholar
• Shinozawa S., Araki Y., Oda T. Tissue distribution and antitumour effect of liposome-entrapped Doxorubicin in Ehrlich solid tumour-bearing mice. Acta Medica Okayama 1981; 35: 395–405
   PubMed Web of Science ®Google Scholar
• Siegfried J. M., Sartorelli A. C., Tritton T. R. Evidence for the lack of relationship between inhibitors of nucleic acid synthesis and cytotoxicity of Adriamycin. Cancer Biochemistry Biophysics 1983; 6: 137–142
   PubMedGoogle Scholar
• Simon W. E., Holzel F. Hormone sensitivity of gynecological tumour cells in tissue culture. Journal of Cancer Research and Clinical Oncology 1979; 94: 307–323
   PubMed Web of Science ®Google Scholar
• Simon W. E., Albrecht M., Hansel M., Dietel M., Holzel F. Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones. Journal of the National Cancer Institute 1983; 70: 839–845
   PubMed Web of Science ®Google Scholar
• Skovssgaard T., Nissen N. I. Membrane transport of anthracyclines. Pharmacology and Therapeutics 1982; 18: 293–311
   PubMed Web of Science ®Google Scholar
• Tokes Z. A., Rogers K. E., Rembaum S. Synthesis of Adriamycin-coupled polyglutaraldehyde microspheres and evaluation of their cytostatic activity. Proceedings of the National Academy of Sciences, U.S.A. 1982; 79: 2026–2030
   PubMed Web of Science ®Google Scholar
• Tritton T. R., Yee G. The antitumor agent Adriamycin can be actively cytotoxic without entering cells. Science 1982; 217: 248–250
   PubMed Web of Science ®Google Scholar
• Van Renswoude J., Hoekstra D. Cell-induced leakage of liposome contents. Biochemistry 1981; 20: 540–546
   PubMed Web of Science ®Google Scholar
• Young R. C., Ozols R. F., Myers C. E. The anthracycline antineoplastic drugs. New England Journal of Medicine 1981; 305: 139–153
   PubMed Web of Science ®Google Scholar